• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Willers, H.
    Krause, M.
    Faivre-Finn, C.
    Chalmers, A. J.
    Affiliation
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    In many patients with cancer, the dose of radiation therapy (RT) that can be safely administered is insufficient to achieve high rates of local tumor control and cure. In others, damage to normal tissues is a concern even at moderate doses. In these settings, RT, or chemoradiation therapy (CRT), ideally would be combined with novel targeted drugs that can enhance the tumoricidal effects of standard therapy but without significantly increased normal tissue toxicity. Over the past decade, major advances in precision medicine have supplied the field of radiation oncology with countless opportunities to enhance the antitumor effects of CRT. However, a large body of preclinical research and clinical investigations on molecular targeted drugs has not yet translated into any meaningful number of combinations of RT or CRT with targeted radiosensitizers that are approved by the US Food and Drug Administration. In fact, to date the epidermal growth factors receptor-directed monoclonal antibody cetuximab remains the only targeted agent approved by the Food and Drug Administration for concurrent administration with RT in head and neck (H&N) cancers. There are considerable challenges to clinical translation of combining targeted drugs with CRT or RT that the field has only recently begun to fully appreciate.
    Citation
    Willers H, Krause M, Faivre-Finn C, Chalmers AJ. Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. Int J Radiat Oncol Biol Phys. 2022;112(2):265-70.
    Journal
    Int J Radiat Oncol Biol Phys
    URI
    http://hdl.handle.net/10541/625047
    DOI
    10.1016/j.ijrobp.2021.10.142
    PubMed ID
    34998527
    Additional Links
    https://dx.doi.org/10.1016/j.ijrobp.2021.10.142
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ijrobp.2021.10.142
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Poly(ADP-ribose) polymerase inhibition: past, present and future.
    • Authors: Curtin NJ, Szabo C
    • Issue date: 2020 Oct
    • Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
    • Authors: Tiwari P, Khan H, Singh TG, Grewal AK
    • Issue date: 2022 Jul
    • Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    • Authors: Rajawat J, Shukla N, Mishra DP
    • Issue date: 2017 Nov
    • Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    • Authors: Parkes EE, Kennedy RD
    • Issue date: 2016 May
    • Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    • Authors: Henning RJ, Bourgeois M, Harbison RD
    • Issue date: 2018 Dec
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.